3.5 Publications

November 6, 2019

Microsatellite Instability Detection with Cell-free DNA Next-generation Sequencing

Society for Immunotherapy of Cancer 2019, Tempus-authored – Microsatellite instability is a clinically actionable genomic indication for cancer immunotherapy. In microsatellite instability-high (MSI-H) tumors, defects in DNA mismatch repair (MMR) can cause a hypermutated phenotype where alterations accumulate in the repetitive microsatellite regions of DNA. MSI detection is typically performed...

November 6, 2019

Detection of Human Leukocyte Antigen Class I Loss of Heterozygosity in Solid Tumor Types by Next-generation DNA Sequencing

Society for Immunotherapy of Cancer 2019, Tempus-authored — Human leukocyte antigen (HLA) class I proteins are expressed on the surface of all nucleated cells and are vital for immune surveillance. When tumor-specific mutations (neoantigens) are presented on HLA molecules to CD8+ T cells, this recognition can drive immune responses against...

November 6, 2019

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

American Society of Hematology 2019, Tempus-authored — Multiple Myeloma (MM) remains a cancer of terminally-differentiated plasma cells that reside predominantly within the bone marrow. Malignant plasma cells are nurtured by a permissive microenvironment that favors tumor progression, drug resistance and disease relapse. Recurrent somatic mutations in hematopoietic stem cells, the...

September 30, 2019

Integrated Genomic Profiling Expands Clinical Options for Patients with Cancer

Nature Biotechnology, Tempus-authored – Genomic analysis of paired tumor–normal samples and clinical data can be used to match patients to cancer therapies or clinical trials. We analyzed 500 patient samples across diverse tumor types using the Tempus xT platform by DNA-seq, RNA-seq and immunological biomarkers. The use of a tumo...

July 23, 2019

Multi-field-of-view Deep Learning Model Predicts Non-small Cell Lung Cancer Programmed Death Ligand-1 Status from Whole-slide Hematoxylin and Eosin Images

Journal of Pathology Informatics, Tempus-authored – Background: Tumor programmed death-ligand 1 (PD-L1) status is useful in determining which patients may benefit from programmed death-1 (PD-1)/PD-L1 inhibitors. However, little is known about the association between PD-L1 status and tumor histopathological patterns. Using deep learning, we predicted PD-L1 status from hema...

May 29, 2019

Resolving Classification of PTEN Variants Using Gene-Specific ACMG/AMP Guidelines: A First Review of Curation Efforts by the ClinGen PTEN Variant Curation Expert Panel

2019 Clingen: Curating the Clinical Genome, Tempus-authored – The ClinGen PTEN Variant Curation Expert Panel (VCEP) provides assessment regarding the pathogenicity of germline PTEN variants with respect to a PTEN Hamartoma Tumor syndrome (MIM+601728) phenotype using PTEN-specific variant classification criteria based on the 2015 ACMG/AMP framework. Of highest priority...

May 26, 2019

Transcriptome-based Cancer Type Prediction for Tumors of Unknown Origin

Journal of Clinical Oncology, Tempus-authored – Background: Tumors of unknown origin occur in approximately 5% of newly diagnosed cancers and are difficult to treat without establishing the tissue type from which they derive. Establishing tumor origin guides standard of care treatment for several NCCN targeted therapy guidelines. Leveraging tissue sp...

May 26, 2019

Real-world Outcomes of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC) and Autoimmune Disease (AD) Receiving Immune Checkpoint Inhibitors (ICIs)

Journal of Clinical Oncology, Tempus-authored – Background: Anecdotal and early evidence suggest ICIs are being used in patients with advanced malignancies and history of AD, despite such patients being typically excluded from traditional clinical trials. We compared the outcomes of patients with or without AD, all of whom had...

May 26, 2019

Real-world Characteristics and Outcomes of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC) Receiving Immune Checkpoint Inhibitor

Journal of Clinical Oncology, Tempus-authored – Background: Immune Checkpoint Inhibitors (ICIs) were first approved for the treatment of aNSCLC in 2014, and since this time have seen rapid adoption in the marketplace. We sought to describe the characteristics of patients with aNSCLC receiving ICIs in the real-world, as well as t...

May 26, 2019

Characteristics of Patients Receiving Immune Checkpoint Inhibitors (ICI) in ASCO’s CancerLinQ

Journal of Clinical Oncology, Tempus-authored – Background: ICI’s have demonstrated significant clinical benefit since the first FDA approval in 2011 of ipilimumab for metastatic melanoma. Five additional ICI therapies have since been approved across several indications. The objectives of this study were to describe the clinical and demograph...

Show More